How does comorbid attention-deficit/hyperactivity disorder (ADHD) affect individuals with substance use disorder (SUD)? Is treatment for ADHD associated with retention in outpatient SUD therapy?
Adult ADHD presents unique challenges for primary care providers. Thus, volunteer primary care and mental health providers created an Adult ADHD Toolkit with information on ADHD and treatment. This study assessed the impact of toolkit implementation.
Do you have patients who take ADHD medication and are planning a pregnancy? How do you respond to questions of safety? This journal CME activity offers evidence.
This study compared the prevalence of depression and suicidal behavior along with the use and cost of related treatment in young adults with and without attention-deficit/hyperactivity disorder using commercial claims data.
This study used post hoc path analyses to examine reciprocal relationships between improvement in executive function and ADHD symptoms from a double-blind, placebo-controlled study of lisdexamfetamine in adults with ADHD. Read on to find out more.
Existing treatments for attention-deficit/hyperactivity disorder (ADHD) in adults, though effective, have limitations. This study examined the efficacy and safety of guanfacine extended-release in adults with ADHD.
Children with ADHD often have functional impairments in the early morning and late afternoon and evening. This study sought to establish norms on 2 rating scales to help clinicians determine when such impairments are clinically significant.
What do patients consider as unmet needs regarding ADHD treatment? This study examined the impairment experienced in the daily life of adults with ADHD currently treated with pharmacotherapy relative to adults without ADHD to identify those needs.
Stimulants are often prescribed to treat ADHD. Here, read about a 6-year-old boy with ADHD who developed excessive daytime sleepiness after starting lisdexamfetamine.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT